Pomerantz Law Firm Investigates Medline Industries Investors for Potential Securities Fraud
Pomerantz LLP is investigating Medline Industries, Inc. (NASDAQ: MDLN) for potential securities fraud and unlawful business practices. The probe follows an FDA warning letter regarding manufacturing violations.
Law firm Pomerantz LLP has launched an investigation into Medline Industries, Inc. (NASDAQ: MDLN) and certain of its officers and/or directors. The probe will examine allegations of securities fraud or other unlawful business practices.
The investigation stems from a warning letter issued by the U.S. Food and Drug Administration (FDA) on June 2, 2026. The FDA letter cited significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. Specifically, the agency stated that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications."
Following the announcement of the FDA's findings, Medline's stock price declined by $2.56 per share, or 7.16 percent, closing at $33.19 on June 2, 2026. Pomerantz LLP is advising investors who have incurred losses in Medline stock to contact the firm.
Pomerantz LLP, with offices in New York and internationally, is a law firm known for its expertise in securities litigation and class actions. The firm has a track record of recovering substantial damages for investors in cases of corporate misconduct.